A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors.
Authors
Pacey, SBlackhall, Fiona H
Garcia-Corbacho, J
Lipplaa, A
Fusi, Alberto
Kumar, S
Hategan, M
Derham, J
Laviste, Glenda
Halford, S
Foxton, C
McLeod, R
Wan, S
Talbot, D
Affiliation
Oncology, Addenbrooke’s Hospital, University of Cambridge, CambridgeIssue Date
2016-10-01
Metadata
Show full item recordCitation
A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors. 2016, 27(suppl_6):1082P Annals of OncologyJournal
Annals of OncologyDOI
10.1093/annonc/mdw383.61Additional Links
https://academic.oup.com/annonc/article/2800154/AType
Meetings and ProceedingsLanguage
enISSN
0923-75341569-8041
ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdw383.61